SCHEMBL2199214

SCHEMBL2199214

Cc1ccc2c(n1)COC2=C1C(=O)Nc2ccc(F)cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPT P10636 1/20 0.39
LRRK2 Q5S007 3/20 0.38
TOP1 P11387 2/20 0.38
KDR P35968 3/20 0.36
PDGFRB P09619 2/20 0.36
KIT P10721 2/20 0.36
CYP2C19 P33261 1/20 0.36
FLT3 P36888 2/20 0.36
RPS6KA3 P51812 1/20 0.35
CDK2 P24941 1/20 0.35
PGR P06401 2/20 0.34
NR3C2 P08235 2/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
AR P10275 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2199212 1.00 MEN1 (0.40) MEN1KMT2AMAPTLRRK2TOP1
SCHEMBL12225649 1.00 MEN1 (0.40) MEN1KMT2AMAPTLRRK2TOP1
SCHEMBL2201338 0.84 ALK (0.38) MEN1KMT2AMAPTLRRK2TOP1
SCHEMBL12225666 0.84 MEN1 (0.38) MEN1KMT2AMAPTLRRK2TOP1
SCHEMBL2201334 0.84 ALK (0.38) MEN1KMT2AMAPTLRRK2TOP1
SCHEMBL2199830 0.84 MEN1 (0.38) MEN1KMT2AMAPTLRRK2TOP1
SCHEMBL2199834 0.84 MEN1 (0.38) MEN1KMT2AMAPTLRRK2TOP1
SCHEMBL12225651 0.84 ALK (0.38) MEN1KMT2AMAPTLRRK2TOP1
SCHEMBL2201924 0.84 MEN1 (0.37) MEN1KMT2ALRRK2TOP1KDR
SCHEMBL12225665 0.84 MEN1 (0.37) MEN1KMT2ALRRK2TOP1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455535-B2 Heteroaryl dihydroindolones as kinase inhibitors ALLERGAN, INC. (US) 2013-06-04 US disclosed
US-20110257238-A1 Heteroaryl Dihydroindolones as Kinase Inhibitors ALLERGAN, INC. (US) 2011-10-20 US disclosed
US-7977351-B2 Heteroaryl dihydroindolones as kinase inhibitors ALLERGAN, INC. (US) 2011-07-12 US disclosed
US-20080045526-A1 HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS ALLERGAN, INC. 2008-02-21 US disclosed
WO-2007109596-A2 HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257238-A1 Heteroaryl Dihydroindolones as Kinase Inhibitors REN, JAK2, ABL1 MEN1 2387/4885KMT2A 442/4885MAPT 4415/4885
US-20080045526-A1 HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS REN, JAK2, ABL1 MEN1 2387/4885KMT2A 442/4885MAPT 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.